Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.

11004Background: The oncogene cyclin-dependent kinase 4 (CDK4) is amplified in > 90% of de-differentiated liposarcomas (DDLS). We previously demonstrated that treatment with the CDK4 inhibitor palb...